Trial reportJournal of substance abuse treatment2010
Smoking outcome by psychiatric history after behavioral and varenicline treatment.
Trial report in Journal of substance abuse treatment, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Nicotine receptor partial agonists for smoking cessation.The Cochrane database of systematic reviews · 2023Pooled it
- Nicotine receptor partial agonists for smoking cessation.The Cochrane database of systematic reviews · 2016Pooled it
- Sex Differences in Varenicline Efficacy for Smoking Cessation: A Meta-Analysis.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2016Pooled it
- Smoking cessation interventions for smokers with current or past depression.The Cochrane database of systematic reviews · 2013Pooled it
- Interventions for smoking cessation and reduction in individuals with schizophrenia.The Cochrane database of systematic reviews · 2013Pooled it
- Flexible, dual-form nicotine replacement therapy or varenicline in comparison with nicotine patch for smoking cessation: a randomized controlled trial.BMC medicine · 2016Trial
- Varenicline for smoking cessation among methadone-maintained smokers: a randomized clinical trial.Drug and alcohol dependence · 2013Trial
- Varenicline for smoking cessation: nausea severity and variation in nicotinic receptor genes.The pharmacogenomics journal · 2012Trial
- Pharmacological Approach to Smoking Cessation: An Updated Review for Daily Clinical Practice.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2020Review
- Extended Nicotine Patch Treatment Among Smokers With and Without Comorbid Psychopathology.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2020Article
- Default mode network deactivation to smoking cue relative to food cue predicts treatment outcome in nicotine use disorder.Addiction biology · 2018Article
- Efficacy and Safety of Varenicline for Smoking Cessation in Schizophrenia: A Meta-Analysis.Frontiers in psychiatry · 2018Article
- Interventions to Address Medical Conditions and Health-Risk Behaviors Among Persons With Serious Mental Illness: A Comprehensive Review.Schizophrenia bulletin · 2016Review
- Quitline Use and Outcomes among Callers with and without Mental Health Conditions: A 7-Month Follow-Up Evaluation in Three States.BioMed research international · 2015Observational
- Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice.British journal of clinical pharmacology · 2014Review
- Two decades of smoking cessation treatment research on smokers with depression: 1990-2010.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2013Review
- Do smoking cessation websites meet the needs of smokers with severe mental illnesses?Health education research · 2012Article
- A Review of Smoking Cessation in Bipolar Disorder: Implications for Future Research.Journal of dual diagnosis · 2012Article
- Varenicline for Smoking Cessation in Schizophrenia: Safety and Effectiveness in a 12-Week, Open-Label Trial.Journal of dual diagnosis · 2012Article
- The smoking cessation drug varenicline improves deficient P20-N40 inhibition in DBA/2 mice.Pharmacology, biochemistry, and behavior · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Treatment outcomes were compared across smokers enrolled in the COMPASS cessation trial with (positive psychiatric history [PH+], n = 271) and without (PH-, n = 271) a diagnosis of PH based on medical record evidence of anxiety, depression, psychotic disorder, or bipolar disorder. Everyone received behavioral counseling plus varenicline and was followed for 6 months post quit date. PH+ smokers took varenicline for fewer days on average (59.4 vs. 68.5, p < or = .01) but did not differ in their use of behavioral treatment. PH+ smokers were more likely to report anxiety and depression, but side-effect intensity ratings did not differ after adjusting for multiple comparisons. Overall, all side effects were rated as moderate intensity or less. Groups had similar 30-day abstinence rates at 6 months (31.5% PH+ vs. 35.4% PH-, p = .35). In sum, having a psychiatric diagnosis in this trial did not predict worse treatment outcome or worse treatment side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.